| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
41,890,000 |
| Market
Cap: |
154.16(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.68 - $3.68 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Neoleukin Therapeutics is a biopharmaceutical company creating immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Co. is initially focused on key cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. Co.'s primary product candidate, NL-201, is a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin-2, or IL-2, and interleukin-15, or IL-15, for the potential treatment of various types of cancer, including renal cell carcinoma, melanoma, and hematological malignancies, while limiting the toxicity caused by the preferential binding of native IL-2 and IL-15 to non-target cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,285,342 |
2,285,342 |
| Total Buy Value |
$0 |
$0 |
$1,463,487 |
$1,463,487 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
1,323 |
26,212 |
| Total Sell Value |
$0 |
$0 |
$818 |
$19,776 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
5 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cobb Stuart |
Chief Scientific Officer |
• – – |
2024-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,391 |
20,391 |
|
- |
|
| Cvijic Christine Mikail |
President and CFO |
• – – |
2024-03-13 |
4 |
A |
$0.00 |
$0 |
D/D |
31,903 |
52,844 |
|
- |
|
| Cvijic Christine Mikail |
President and CFO |
• – – |
2023-12-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,941 |
|
- |
|
| Mcminn Rachel |
Chief Executive Officer |
• • – |
2023-12-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,250,359 |
|
- |
|
| Baker Bros. Advisors (gp) Llc |
Director |
– • • |
2023-10-05 |
4 |
OE |
$0.00 |
$0 |
I/I |
592,650 |
1,658,190 |
|
- |
|
| Baker Bros. Advisors (gp) Llc |
Director |
– • • |
2023-08-17 |
4 |
B |
$0.69 |
$115,617 |
I/I |
166,942 |
5,612,949 |
2.25 |
- |
|
| Baker Bros. Advisors (gp) Llc |
Director |
– • • |
2023-08-16 |
4 |
B |
$0.68 |
$156,254 |
I/I |
229,600 |
5,458,724 |
2.25 |
- |
|
| Baker Bros. Advisors (gp) Llc |
Director |
– • • |
2023-08-15 |
4 |
B |
$0.63 |
$1,191,616 |
I/I |
1,888,800 |
5,246,614 |
2.25 |
- |
|
| Smith Sean Michael |
Interim CFO, Prin Acct Off |
• – – |
2023-08-11 |
4 |
S |
$0.62 |
$818 |
D/D |
(1,323) |
21,637 |
|
- |
|
| Smith Sean Michael |
Interim CFO, Prin Acct Off |
• – – |
2023-08-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
22,960 |
|
- |
|
| Patel Priti |
Chief Medical Officer |
• – – |
2023-02-02 |
4 |
S |
$0.60 |
$8,588 |
D/D |
(14,380) |
31,082 |
|
- |
|
| Smith Sean Michael |
Principal Accounting Officer |
• – – |
2023-02-02 |
4 |
S |
$0.60 |
$1,980 |
D/D |
(3,316) |
15,960 |
|
- |
|
| Patel Priti |
Chief Medical Officer |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
45,462 |
|
- |
|
| Smith Sean Michael |
Principal Accounting Officer |
• – – |
2023-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
19,276 |
|
- |
|
| Smith Sean Michael |
Principal Accounting Officer |
• – – |
2022-08-10 |
4 |
S |
$0.99 |
$1,641 |
D/D |
(1,655) |
6,776 |
|
- |
|
| Smith Sean Michael |
Principal Accounting Officer |
• – – |
2022-08-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
8,431 |
|
- |
|
| Patel Priti |
Chief Medical Officer |
• – – |
2022-05-02 |
4 |
S |
$1.22 |
$6,749 |
D/D |
(5,538) |
6,462 |
|
- |
|
| Patel Priti |
Chief Medical Officer |
• – – |
2022-04-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
12,000 |
|
- |
|
| Smith Sean Michael |
Principal Accounting OfficerOf |
• – – |
2022-03-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,431 |
|
- |
|
| Drachman Jonathan G |
President and CEO |
• • – |
2021-08-25 |
4 |
B |
$6.45 |
$322,450 |
I/I |
50,000 |
25,000 |
2.66 |
- |
|
| Drachman Jonathan G |
President and CEO |
• • – |
2021-08-24 |
4 |
B |
$6.11 |
$611,100 |
D/D |
100,000 |
2,348,686 |
2.81 |
- |
|
| Walkey Carl |
Senior Vice President |
• – – |
2021-06-16 |
4 |
AS |
$10.19 |
$6,114 |
D/D |
(600) |
1,352,489 |
|
- |
|
| Walkey Carl |
Senior Vice President |
• – – |
2021-06-09 |
4 |
AS |
$10.82 |
$7,036 |
D/D |
(650) |
1,353,089 |
|
- |
|
| Walkey Carl |
Senior Vice President |
• – – |
2021-06-08 |
4 |
AS |
$11.00 |
$6,600 |
D/D |
(600) |
1,353,739 |
|
- |
|
| Walkey Carl |
Senior Vice President |
• – – |
2021-06-04 |
4 |
AS |
$10.00 |
$6,000 |
D/D |
(600) |
1,354,339 |
|
- |
|
154 Records found
|
|
Page 1 of 7 |
|
|
